Startups
Edit
Trovagene, Inc.
http://www.trovagene.com/Last activity: 28.10.2019
Active - Reference to Cardiff Oncology
Trovagene is a biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.
Trovagene's lead therapeutic asset is PCM-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (PLK1) inhibitor for the treatment of acute myeloid leukemia (AML). Among the four members of the PLK family, PLK1 is recognized to be the fundamental component for cell division to take place correctly. Most importantly, PLK1 is only expressed in dividing cells, whereas other PLK members are expressed in differentiated post-mitotic cells, like neurons, indicating a potentially better safety profile for a PLK1-selective inhibitor, such as PCM-075. The greatest clinical activity for PLK inhibitors has been observed in AML, which may likely be due to the highly proliferative nature of AML tumors. Trovagene's interest in PLK inhibitors stems from this observed PLK clinical activity and the opportunity for a more selective therapeutic approach. The properties of PCM-075 are PLK1 selectivity, the only orally-available PLK inhibitor in clinical development, a short half-life of ~24 hours with reversible hematologic toxicities, and an acceptable safety profile in humans with no adverse respiratory or cardiovascular effects. Trovagene plans to conduct a phase II trial for determining dose, patient response and correlative biomarker analysis for patients with AML.
For more information, please visit our website www.trovagene.com.
Trovagene's lead therapeutic asset is PCM-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (PLK1) inhibitor for the treatment of acute myeloid leukemia (AML). Among the four members of the PLK family, PLK1 is recognized to be the fundamental component for cell division to take place correctly. Most importantly, PLK1 is only expressed in dividing cells, whereas other PLK members are expressed in differentiated post-mitotic cells, like neurons, indicating a potentially better safety profile for a PLK1-selective inhibitor, such as PCM-075. The greatest clinical activity for PLK inhibitors has been observed in AML, which may likely be due to the highly proliferative nature of AML tumors. Trovagene's interest in PLK inhibitors stems from this observed PLK clinical activity and the opportunity for a more selective therapeutic approach. The properties of PCM-075 are PLK1 selectivity, the only orally-available PLK inhibitor in clinical development, a short half-life of ~24 hours with reversible hematologic toxicities, and an acceptable safety profile in humans with no adverse respiratory or cardiovascular effects. Trovagene plans to conduct a phase II trial for determining dose, patient response and correlative biomarker analysis for patients with AML.
For more information, please visit our website www.trovagene.com.
Overview
Phone
+1 858-952-7570
Total raised
$21.5M
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Apr 5, 2019 | Funding round | $1.5M | |
| Jul 31, 2013 | Funding round | $15M |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 5, 2019 | Trovagene Gets $1.5M In PIPE For Oncology Drug Efforts | San Diego-based oncology therapeutics developer Trovagene, which is publicly listed on the Nasdaq as TROV, said it has received a $1.5M, private placement. The new investment came from Lincoln Park Capital. According to Trovagene, the new f... |
| Jan 10, 2016 | The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening? | But other companies have been touting advances in liquid biopsy screening for some time now. This is hardly the first gander at a pan-cancer test, right? San Diego-based Pathway Genomics, for instance, announced this past summer that it had... |
| Mar 13, 2015 | Trovagene Announces $4.7 Million Net Loss for Q4 | San Diego-based Trovagene Inc., a molecular diagnostics company, announced its fourth quarter financial results on March 13, reporting a net loss of $4.7 million on revenue of $56,000. In the same quarter of 2013, the company reported a net... |
| Jul 1, 2014 | Trovagene Secures Debt Facility of $15 Million | Trovagene Inc., a San Diego molecular diagnostics company, said it secured an unrestricted debt facility of $15 million from Silicon Valley bank and Oxford Finance LLC. The company said the additional capital will be used to support ongoing... |
| Jul 31, 2013 | Trovagene Raises $15M In PIPE | San Diego-based molecular diagnostics developer Trovagene announced this morning that it has raised $15M in a registered direct offering of its common stock. The publicly held company, which trades on the NASDAQ as TROV, said the shares wer... |
| The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening? | On the eve of this year’s J.P. Morgan Healthcare Conference, Illumina made a much-hyped announcement: With $100 million in Series A funding, it just launched Grail, a diagnostics startup that is developing a pan-cancer blood test. The circu... |
Reviews 0
FAQ about Trovagene, Inc.
How much funding has Trovagene, Inc. raised?
Trovagene, Inc. has raised $21.5M in total across 3 funding rounds.
What funding rounds has Trovagene, Inc. raised?
Parsers VC lists 3 funding rounds of Trovagene, Inc., among them a funding round of $1.5M on Apr 5, 2019 and a funding round of $15M on Jul 31, 2013.
What has the press written about Trovagene, Inc.?
Parsers VC has collected 7 articles mentioning Trovagene, Inc., among them “Trovagene Gets $1.5M In PIPE For Oncology Drug Efforts” (Apr 5, 2019) and “The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening?” (Jan 10, 2016).
Is Trovagene, Inc. still active?
Yes, Trovagene, Inc. is active; its latest activity on Parsers VC dates from Oct 28, 2019.